Cisplatin Renal Toxicity Working Group (CRT)

Home / Cisplatin Renal Toxicity Working Group (CRT)

Cisplatin Renal Toxicity Working Group

Cisplatin, and other platinum salts, still are the cornerstone of a number of tumor treatments. Although these drugs have been available for years, renal toxicity still is an issue in clinical practice, with some recent studies reporting as high as 30% of patients presenting with acute kidney injury. Methods of prevention exist, and the prevention of dehydration is key. In this view, providing patients with optimal and appropriate prevention of chemotherapy-induced nausea and vomiting appears to be of a crucial importance.

The most recent recommendations from a scientific society published in the literature (Launay-Vacher V et al. insisted on the hydration of the patient, the avoidance of concurrent nephrotoxic therapy, and the question of diuretics.

The C-KIN Working Group is aiming at developing updated clinical practice recommendations on the prevention of cisplatin renal toxicity through an evidence-based analysis of the existing literature, and with a specific focus on the prevention of chemotherapy-induced nausea and vomiting, which can be a cause for dehydration, and secondary drug tubular toxicity.

Members of the CRT

  • Chair: Florian Scotté – France – Oncology
  • co-Chair Vincent Launay-Vacher – France – Clinical Pharmacology
  • Jørn Herrstedt – Denmark – Oncology
  • Mario Dicato – Luxembourg – Haematology-Oncology
  • Karin Jordan – Germany – Haematology/Oncology
  • Richard Gralla – USA – Oncology
  • Fausto Roila – Italy – Oncology
  • Matti Aapro – Switzerland – Oncology
#list-style-5c47376fdb7eb ul li:before { font-family:Icomoon; content: "\e094"; color:#1866ad }

For more information about the CRT, please contact us at

LogoHelsinn (002)

The C-KIN CRT is supported by a Helsinn grant.

About the Helsinn Group
Helsinn, a privately-owned Swiss pharmaceutical group focused on building quality cancer care has an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity, quality, through a unique licensing business model and working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Headquartered in Switzerland, Helsinn has an operating subsidiary in the USA with direct local sales and marketing, GMP manufacturing facilities in Switzerland and Ireland, and a representative office in China.



The C-KIN CRT is supported by a Tesaro grant.

About Tesaro

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.